The pair continued to carry out exploratory research ... Its in-house pipeline is headed by MORF-057, an orally-available alpha 4 beta 7 integrin inhibitor that is currently in phase 2 testing ...

The deal is expected to close sometime in the third quarter. MORF-057 is an α4β7 integrin inhibitor currently in a pair of phase 2 trials in ulcerative colitis and a third in Crohn’s disease.